Directing and Potentiating our Immune System
Developing next generation immune modulating therapeutics which direct and potentiate both innate and adaptive immunity
OUR MISSION
At FuseBio, we are dedicated to developing transformative immune modulating therapeutics for patients with cancer. Our therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that spare healthy tissues.
OUR SCIENCE
Using our team’s deep understanding of T cell and Natural Killer (NK) cell biology, FuseBio’s pipeline of multi-functional antibodies leverages the inherent capacity of NK cells to distinguish between normal and diseased tissue.
Our platform transforms antibodies into danger sensing therapeutics that utilize NK cell education as an ON/OFF switch to deploy highly potent immune stimulating cargo that vigorously enhances an immune response to eradicate tumors without killing a patient’s healthy tissue.
OUR TEAM
We have assembled a world-class team comprised of industry, clinical and academic experts, with deep knowledge in NK and T cell biology, immuno-oncology and protein engineering. The fusion of innovation and industry level development is deeply rooted in translational drug discovery and is maximized through our deep ties to renowned academic institutions. By coupling our development roadmap with our experience in clinical operations, regulatory affairs and commercialization, we have designed an effective, efficient and highly differentiated model to benefit patients in a seamless and rapid manner.
management team & co-founders
Paul Y. Song, MD
Chief Executive Officer
Jeffrey Takimoto, Ph.D
Chief Business Officer &
Chief Financial Officer
Brian Rabinovich, Ph.D
Chief Scientific Officer
Evren Alici, MD, Ph.D
Head of Scientific Advisory Board at FuseBio &
Head of Cell and Gene Therapy Group at Karolinska Institutet
